3
Supplemental Figure 1 Mock MOI-10 MOI-100 0 5 10 15 20 25 1.45 6.16 19.74 [18F]-FHBG Uptake in NY-ESO-1- TCR/sr39TK Transduced Jurkat Cells Normalized Uptake C B A NY-ESO-1 Tetramer PE CD3 PerCP 79.7% 21.8% 0.5% Mock MOI-10 MOI-100 EC 50 ofJurkats w ith G anciclovir 10 -1 5 10 -1 2 10 -9 10 -6 10 -3 0 20 40 60 80 100 EC50 Mock 0.0002888 MOI-10 6.370e-011 MOI-100 8.454e-011 Medium Only 0.0004830 R square Mock 0.9483 MOI-10 0.9773 MOI-100 0.9727 Medium Only 0.9144 M ock M OI-10 M OI-100 M edium Only [G anciclovir](M ) % V iab le C ells (N orm alized )

Supplemental Figure 1

  • Upload
    selina

  • View
    53

  • Download
    1

Tags:

Embed Size (px)

DESCRIPTION

Supplemental Figure 1. A. Mock. MOI-100. MOI-10. 0.5%. 79.7%. 21.8%. CD3 PerCP. NY-ESO-1 Tetramer PE. B. C. Supplemental Figure 2. A. Thymus. L Humerus. R Humerus. Muscle. L Femur. R Femur. C. B. P < 0.0001. Supplemental Figure 3. A. B. - PowerPoint PPT Presentation

Citation preview

Page 1: Supplemental Figure 1

Supplemental Figure 1

Mock MOI-10 MOI-1000

5

10

15

20

25

1.45

6.16

19.74

[18F]-FHBG Uptake in NY-ESO-1-TCR/sr39TK Transduced Jurkat Cells

No

rma

lize

d U

pta

ke

EC50 of Jurkats with Ganciclovir

10- 1 5 10- 1 2 10- 9 10- 6 10- 3

0

20

40

60

80

100

EC50Mock

0.0002888MOI-10

6.370e-011MOI-100

8.454e-011Medium Only0.0004830

R squareMock

0.9483MOI-100.9773

MOI-1000.9727

Medium Only0.9144

MockMOI-10MOI-100Medium Only

[Ganciclovir] (M)

% V

iab

le C

ells

(N

orm

aliz

ed)

C

B

A

NY-ESO-1 Tetramer PE

CD

3 P

erC

P

79.7%21.8%0.5%

Mock MOI-10 MOI-100

Page 2: Supplemental Figure 1

B

Supplemental Figure 2

Thymus

L Humerus

Muscle

L Femur

R Humerus

R Femur

A

In Vivo [18F]-FHBG Uptake

% I

D/g

(b

kg

d s

ub

tra

cte

d)

Mock ESO/TK

0

2

4

6

8P < 0.0001

Non-Transduced Humanized

% ID

/g (

bkg

d s

ub

trac

ted

)

NT1 NT2 NT3 NT1 NT2 NT3

0

2

4

6

8

C

Page 3: Supplemental Figure 1

Supplemental Figure 3

V1

V2

V3

V4

V5

V6

V7

V8/9

0 5 10 15 20 25 30 35 40 45 50

ψ Neg ψ Pos

%hCD45

A B


Supplemental Material Supplemental Figure 1. Further Analysis of … · 2013-04-17 · ! 1! Supplemental Material Supplemental Figure 1. Further Analysis of CX3CR1 Expressing Myeloid

Supplemental Material Supplemental Figure 1. Further Analysis of … · 2013-04-17 · ! 1! Supplemental Material Supplemental Figure 1. Further Analysis of CX3CR1 Expressing Myeloid

Documents
Supplemental Figure 1

Supplemental Figure 1

Documents
Supplemental Figure 1 - Journal of CancerSupplemental Figure 2 . Supplemental Figure 3 . Supplemental Table 1. Relationship between CD4 TIL expression and various patient characteristics

Supplemental Figure 1 - Journal of CancerSupplemental Figure 2 . Supplemental Figure 3 . Supplemental Table 1. Relationship between CD4 TIL expression and various patient characteristics

Documents
Supplemental Figure Legends: Supplemental Figure S1 ...genesdev.cshlp.org/content/suppl/2014/07/11/gad... · Supplemental Figure Legends: Supplemental Figure S1 Vernalization response

Supplemental Figure Legends: Supplemental Figure S1 ...genesdev.cshlp.org/content/suppl/2014/07/11/gad... · Supplemental Figure Legends: Supplemental Figure S1 Vernalization response

Documents
Supplemental Figure 1

Supplemental Figure 1

Documents
Supplemental Figure Legend Supplemental Figure 1 A · Supplemental Figure Legend Supplemental Figure 1 (A) Principal component analysis of gene expression of Panc-1 and BxPC3 cells.All

Supplemental Figure Legend Supplemental Figure 1 A · Supplemental Figure Legend Supplemental Figure 1 (A) Principal component analysis of gene expression of Panc-1 and BxPC3 cells.All

Documents
SUPPLEMENTAL FIGURE LEGEND - Weeblydimitrovagen677s09.weebly.com/uploads/1/7/2/1/...1 SUPPLEMENTAL FIGURE LEGEND Supplemental Figure 1. Absence of cardiac developmental abnormalities

SUPPLEMENTAL FIGURE LEGEND - Weeblydimitrovagen677s09.weebly.com/uploads/1/7/2/1/...1 SUPPLEMENTAL FIGURE LEGEND Supplemental Figure 1. Absence of cardiac developmental abnormalities

Documents
Supplemental data: Supplemental Figure 1. Sequence of

Supplemental data: Supplemental Figure 1. Sequence of

Documents
Supplemental Figure 1. Supplemental Figure 2 Supplemental Figure 3 A B

Supplemental Figure 1. Supplemental Figure 2 Supplemental Figure 3 A B

Documents
List of Supplemental Digital Content Supplemental Figure 1

List of Supplemental Digital Content Supplemental Figure 1

Documents
Supplemental Figure 1

Supplemental Figure 1

Documents
Supplemental Figure 7(1) p u t SUPPLEMENTAL FIGURE 2 A B H3K4me3 loci Title Supplemental Figure 7(1).ai Created Date 20161030123200Z

Supplemental Figure 7(1) p u t SUPPLEMENTAL FIGURE 2 A B H3K4me3 loci Title Supplemental Figure 7(1).ai Created Date 20161030123200Z

Documents
BolteusBordey Supplemental Figure 1

BolteusBordey Supplemental Figure 1

Documents
SUPPLEMENTAL FIGURE LEGENDS Supplemental Fig… · SUPPLEMENTAL FIGURE LEGENDS Supplemental Fig. 1. ... Schematic representation of zebrafish ATX gene with exons ... LPA 1 MO caused

SUPPLEMENTAL FIGURE LEGENDS Supplemental Fig… · SUPPLEMENTAL FIGURE LEGENDS Supplemental Fig. 1. ... Schematic representation of zebrafish ATX gene with exons ... LPA 1 MO caused

Documents
SUPPLEMENTAL FIGURE LEGENDS Supplemental Figure 1 (A,B) (C ...dm5migu4zj3pb.cloudfront.net/manuscripts/65000/65899/JCI65899sd.pdf · Supplemental Figure 1 Siglec-7 and -9 ligand expression

SUPPLEMENTAL FIGURE LEGENDS Supplemental Figure 1 (A,B) (C ...dm5migu4zj3pb.cloudfront.net/manuscripts/65000/65899/JCI65899sd.pdf · Supplemental Figure 1 Siglec-7 and -9 ligand expression

Documents
Supplemental Tables and Supplemental Figure Legends...2014/04/14  · 1 Supplemental Tables and Supplemental Figure Legends 2 3 Supplementary Figure Legends 4 5 Figure S1. SDS-PAGE

Supplemental Tables and Supplemental Figure Legends...2014/04/14  · 1 Supplemental Tables and Supplemental Figure Legends 2 3 Supplementary Figure Legends 4 5 Figure S1. SDS-PAGE

Documents
Supplemental Figure Legends: Supplemental Figure 1 ...dm5migu4zj3pb.cloudfront.net/manuscripts/59000/59743/JCI...31 Supplemental Figure Legends: Supplemental Figure 1. Caerulein treatment

Supplemental Figure Legends: Supplemental Figure 1 ...dm5migu4zj3pb.cloudfront.net/manuscripts/59000/59743/JCI...31 Supplemental Figure Legends: Supplemental Figure 1. Caerulein treatment

Documents
1. Supplemental Figure 1 - International Journal of ... · Supplemental Figure 1 2. Supplemental Figure 2 3. Supplemental Figure 3 4. Supplemental Figure 4 5. Supplemental Figure

1. Supplemental Figure 1 - International Journal of ... · Supplemental Figure 1 2. Supplemental Figure 2 3. Supplemental Figure 3 4. Supplemental Figure 4 5. Supplemental Figure

Documents
Supplemental figure 1: Dapul_304363

Supplemental figure 1: Dapul_304363

Documents
Supplemental Figure 1 A. · Supplemental Figure 1 A. B. Let-7 target site C. miR-103/107 target site . 2 Supplemental Figure 2 . 3 Supplemental Figure 3 . 4 Supplemental Figure 4

Supplemental Figure 1 A. · Supplemental Figure 1 A. B. Let-7 target site C. miR-103/107 target site . 2 Supplemental Figure 2 . 3 Supplemental Figure 3 . 4 Supplemental Figure 4

Documents
Figure legends: Supplemental Figure 1 A) TAA;

Figure legends: Supplemental Figure 1 A) TAA;

Documents
Supplemental Figures Supplemental Figure 1€¦ · Supplemental Figures . Supplemental Figure 1 . Supplemental Figure 1. AdipoChaser mouse models used for cold and thermoneutral exposures

Supplemental Figures Supplemental Figure 1€¦ · Supplemental Figures . Supplemental Figure 1 . Supplemental Figure 1. AdipoChaser mouse models used for cold and thermoneutral exposures

Documents
Supplemental Digital Content Supplemental Figure 1

Supplemental Digital Content Supplemental Figure 1

Documents